McAdam LLC’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

McAdam LLC’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-80	Closed	-$10K	–	659
2018 Q3	$10K	Hold	80	–	–	﹤0.01%	343
2018 Q2	$7K	Buy	+80	New	+$5.86K	﹤0.01%	365

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

McAdam LLC's ICPT Position: Q4 2018 in Review

McAdam LLC sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2018, closing a stake of 80 shares — an estimated $10K sold.

McAdam LLC first reported a position in ICPT in Q2 2018 and held it in 2 quarters. The position peaked at $10K in Q3 2018. 191 funds tracked by Wall St. Rank hold ICPT as of Q4 2018.

McAdam LLC reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 80 Intercept Pharmaceuticals, Inc. shares in Q4 2018, an estimated $10K.
McAdam LLC first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
McAdam LLC's Intercept Pharmaceuticals, Inc. position peaked at $10K in Q3 2018.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.